Quick Answer
Apogee Therapeutics, Inc. reported Net Income Loss of -$255.84 million for the year ending 2025.
- Apogee Therapeutics, Inc. showed a decrease of -40.5% in Net Income Loss from 2024 to 2025.
- This data is from Apogee Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$4.31 million | Q2 2022: -$1.82 million | Q3 2022: -$19.66 million | Q1 2023: -$12.53 million | Q2 2023: -$18.89 million | Q3 2023: -$20.84 million | Q1 2024: -$32.09 million | Q2 2024: -$33.82 million | Q3 2024: -$49.02 million | Q1 2025: -$55.34 million | Q2 2025: -$66.10 million | Q3 2025: -$65.02 million.
- Over the full 4 years of available data (2022 to 2025), Apogee Therapeutics, Inc.'s Net Income Loss has declined by 543.1%.
- Historical annual values: Fiscal year 2025: -$255.84 million | Fiscal year 2024: -$182.15 million | Fiscal year 2023: -$83.99 million | Fiscal year 2022: -$39.79 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: